Chemomab Therapeutics has filed a patent for compositions and methods to treat fibrotic inflammatory diseases, such as NASH, PSC, and SSc, using an anti-CCL24 monoclonal antibody. The patent claim details have been canceled. GlobalData’s report on Chemomab Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Chemomab Therapeutics Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Chemomab Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Chemomab Therapeutics's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of fibrotic inflammatory diseases with anti-ccl24 monoclonal antibody

Source: United States Patent and Trademark Office (USPTO). Credit: Chemomab Therapeutics Ltd

A recently filed patent (Publication Number: US20230235037A1) describes a method for treating fibrotic inflammatory diseases in humans using a humanized anti-CCL24 monoclonal antibody. The patent claims that administering this antibody at specific doses can effectively treat diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cholestatic liver diseases, primary sclerosing cholangitis (PSC), or systemic sclerosis (SSC).

The method involves administering the anti-CCL24 monoclonal antibody subcutaneously or intravenously, at doses of about 2.5 mg/kg, 5 mg/kg, 10 mg/kg, or 20 mg/kg. The administration frequency can range from once every one to four weeks, and the treatment duration can be at least four weeks, 15 weeks, or 24 weeks.

The patent also suggests evaluating the level of circulating fibrosis markers to determine the improvement in the hepatic condition of the subject. These markers include plasma alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), PRO-C3, PRO-C4, PRO-05, C3M, cytokeratin 18 (CK18), amino-terminal propeptide of type III procollagen (PIIINP), hyaluronic acid (HA), Tissue Inhibitor of Metalloproteinases 1 (TIMP-1), platelet-derived growth factor (PDGF), Tissue Inhibitor of Metalloproteinases 2 (TIMP-2), ?-glutamyltransferase (GGT), bilirubin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT).

The patent also describes a pharmaceutical composition containing the anti-CCL24 monoclonal antibody, with specific concentrations and buffers. The composition may include histidine buffer, sodium or potassium phosphate buffer, arginine, glutamic acid, sorbitol, glycine, and polysorbate. The pH of the composition can range from 5 to 8, and it can be supplied in unit doses with fill volumes of 0.2 to 2 mL or 5 to 20 mL.

Additionally, the patent mentions a kit that includes the pharmaceutical composition and instructions for use.

Overall, this patent proposes a method for treating fibrotic inflammatory diseases using a specific humanized anti-CCL24 monoclonal antibody. The method involves administering the antibody at specific doses and frequencies, evaluating the hepatic condition using circulating fibrosis markers, and utilizing a pharmaceutical composition with specific concentrations and buffers.

To know more about GlobalData’s detailed insights on Chemomab Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies